121 related articles for article (PubMed ID: 26593062)
1. Structure-Activity Relationship Studies of Amino Acid Substitutions in Radiolabeled Neurotensin Conjugates.
Mascarin A; Valverde IE; Mindt TL
ChemMedChem; 2016 Jan; 11(1):102-7. PubMed ID: 26593062
[TBL] [Abstract][Full Text] [Related]
2. Comparative study on DOTA-derivatized bombesin analog labeled with 90Y and 177Lu: in vitro and in vivo evaluation.
Koumarianou E; Mikołajczak R; Pawlak D; Zikos X; Bouziotis P; Garnuszek P; Karczmarczyk U; Maurin M; Archimandritis SC
Nucl Med Biol; 2009 Aug; 36(6):591-603. PubMed ID: 19647165
[TBL] [Abstract][Full Text] [Related]
3. Novel DOTA-neurotensin analogues for 111In scintigraphy and 68Ga PET imaging of neurotensin receptor-positive tumors.
Alshoukr F; Prignon A; Brans L; Jallane A; Mendes S; Talbot JN; Tourwé D; Barbet J; Gruaz-Guyon A
Bioconjug Chem; 2011 Jul; 22(7):1374-85. PubMed ID: 21662976
[TBL] [Abstract][Full Text] [Related]
4. Stabilised 111In-labelled DTPA- and DOTA-conjugated neurotensin analogues for imaging and therapy of exocrine pancreatic cancer.
de Visser M; Janssen PJ; Srinivasan A; Reubi JC; Waser B; Erion JL; Schmidt MA; Krenning EP; de Jong M
Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1134-9. PubMed ID: 12768332
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of DOTA-chelated neurotensin analogs with spacer-enhanced biological performance for neurotensin-receptor-1-positive tumor targeting.
Jia Y; Shi W; Zhou Z; Wagh NK; Fan W; Brusnahan SK; Garrison JC
Nucl Med Biol; 2015 Nov; 42(11):816-23. PubMed ID: 26302836
[TBL] [Abstract][Full Text] [Related]
6. Methoxinine - an alternative stable amino acid substitute for oxidation-sensitive methionine in radiolabelled peptide conjugates.
Grob NM; Behe M; von Guggenberg E; Schibli R; Mindt TL
J Pept Sci; 2017 Jan; 23(1):38-44. PubMed ID: 28054429
[TBL] [Abstract][Full Text] [Related]
7. 1,2,3-Triazole Stabilized Neurotensin-Based Radiopeptidomimetics for Improved Tumor Targeting.
Mascarin A; Valverde IE; Vomstein S; Mindt TL
Bioconjug Chem; 2015 Oct; 26(10):2143-52. PubMed ID: 26347939
[TBL] [Abstract][Full Text] [Related]
8. Imaging Neurotensin Receptor in Prostate Cancer With
Deng H; Wang H; Zhang H; Wang M; Giglio B; Ma X; Jiang G; Yuan H; Wu Z; Li Z
Mol Imaging; 2017; 16():1536012117711369. PubMed ID: 28849698
[TBL] [Abstract][Full Text] [Related]
9. Novel bioactive and stable neurotensin peptide analogues capable of delivering radiopharmaceuticals and molecular beacons to tumors.
Achilefu S; Srinivasan A; Schmidt MA; Jimenez HN; Bugaj JE; Erion JL
J Med Chem; 2003 Jul; 46(15):3403-11. PubMed ID: 12852770
[TBL] [Abstract][Full Text] [Related]
10. Characterization of a radiolabeled small molecule targeting leukocyte function-associated antigen-1 expression in lymphoma and leukemia.
Poria RB; Norenberg JP; Anderson TL; Erion J; Wagner CR; Arterburn JB; Larson RS
Cancer Biother Radiopharm; 2006 Oct; 21(5):418-26. PubMed ID: 17105416
[TBL] [Abstract][Full Text] [Related]
11. Syntheses, receptor bindings, in vitro and in vivo stabilities and biodistributions of DOTA-neurotensin(8-13) derivatives containing β-amino acid residues - a lesson about the importance of animal experiments.
Sparr C; Purkayastha N; Yoshinari T; Seebach D; Maschauer S; Prante O; Hübner H; Gmeiner P; Kolesinska B; Cescato R; Waser B; Reubi JC
Chem Biodivers; 2013 Dec; 10(12):2101-21. PubMed ID: 24327436
[TBL] [Abstract][Full Text] [Related]
12. Novel stable analogues of the neurotensin C-terminal hexapeptide containing unnatural amino acids.
Magafa V; Matsoukas MT; Karageorgos V; Dermitzaki E; Exarchakou R; Stylos EΚ; Pardalos M; Margioris AN; Varvounis G; Tzakos AG; Spyroulias GA; Liapakis G
Amino Acids; 2019 Jul; 51(7):1009-1022. PubMed ID: 31079216
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, proteolytic stability, and
Kaur J; Arroub K; Drzezga A; Schomäcker K; Mathur S
Org Biomol Chem; 2021 Nov; 19(45):9849-9854. PubMed ID: 34755753
[TBL] [Abstract][Full Text] [Related]
14. Preclinical evaluation of a new, stabilized neurotensin(8--13) pseudopeptide radiolabeled with (99m)tc.
García-Garayoa E; Bläuenstein P; Bruehlmeier M; Blanc A; Iterbeke K; Conrath P; Tourwé D; Schubiger PA
J Nucl Med; 2002 Mar; 43(3):374-83. PubMed ID: 11884498
[TBL] [Abstract][Full Text] [Related]
15. Preclinical PET Imaging of NTSR-1-Positive Tumors with
Li D; Minnix M; Allen R; Bading J; Chea J; Wong P; Bowles N; Poku E; Shively JE
Cancer Biother Radiopharm; 2021 Oct; 36(8):651-661. PubMed ID: 32822229
[No Abstract] [Full Text] [Related]
16. Novel neurotensin analogues for radioisotope targeting to neurotensin receptor-positive tumors.
Alshoukr F; Rosant C; Maes V; Abdelhak J; Raguin O; Burg S; Sarda L; Barbet J; Tourwé D; Pelaprat D; Gruaz-Guyon A
Bioconjug Chem; 2009 Aug; 20(8):1602-10. PubMed ID: 19610615
[TBL] [Abstract][Full Text] [Related]
17. PEG spacers of different length influence the biological profile of bombesin-based radiolabeled antagonists.
Jamous M; Tamma ML; Gourni E; Waser B; Reubi JC; Maecke HR; Mansi R
Nucl Med Biol; 2014 Jul; 41(6):464-70. PubMed ID: 24780298
[TBL] [Abstract][Full Text] [Related]
18. A cyclen-based tetraphosphinate chelator for the preparation of radiolabeled tetrameric bioconjugates.
Šimeček J; Hermann P; Havlíčková J; Herdtweck E; Kapp TG; Engelbogen N; Kessler H; Wester HJ; Notni J
Chemistry; 2013 Jun; 19(24):7748-57. PubMed ID: 23613345
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluation of a novel (177)Lu-DOTA-[Gly(3)-cyclized(Dap(4), (d)-Phe(7), Asp(10))-Arg(11)]α-MSH(3-13) analogue for melanocortin-1 receptor-positive tumor targeting.
Lim JC; Hong YD; Kim JJ; Choi SM; Baek HS; Choi SJ
Cancer Biother Radiopharm; 2012 Oct; 27(8):464-72. PubMed ID: 22831553
[TBL] [Abstract][Full Text] [Related]
20. DOTA conjugate with an albumin-binding entity enables the first folic acid-targeted 177Lu-radionuclide tumor therapy in mice.
Müller C; Struthers H; Winiger C; Zhernosekov K; Schibli R
J Nucl Med; 2013 Jan; 54(1):124-31. PubMed ID: 23236020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
